ReviewPharmaceuticals (Basel, Switzerland)2020
Tumor Immunotherapy Using A
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04969315 (Phase I/II First-in-Human Study of TT-10), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Novel Fluorophenylated Dihydroimidazotriazinones as Potential Anticancer Agents: Design, Synthesis, In Vitro, Ex Vivo and In Silico Characterisation.International journal of molecular sciences · 2026Article
- Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer.Discover oncology · 2026Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Neoantigen mRNA vaccines and AHuman vaccines & immunotherapeutics · 2025Review
- Therapeutic potential of adenosine receptor modulators in cancer treatment.RSC advances · 2025Review
- Insights from Clinical Trials on AACS pharmacology & translational science · 2025Review
- Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.International journal of molecular sciences · 2023Review
- Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives.Pharmaceutics · 2023Review
- AInternational review of neurobiology · 2023Article
- Special Issue "GPCRs: Ligands and beyond 2022".Pharmaceuticals (Basel, Switzerland) · 2022Article
- Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization.Communications biology · 2022Article
- EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation.Frontiers in immunology · 2022Article
- Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management.Frontiers in immunology · 2022Review
- Adenosine Receptor Antagonists as Potential Cancer Therapy.ACS medicinal chemistry letters · 2021Article
- Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward.Journal for immunotherapy of cancer · 2021Review
- Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients-Mechanism of Action and Future Concepts.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.